AP NEWS

Bioasis Announces Agreement With Leading Pharmaceutical Company for Pre-Clinical Research Using the xB3 Platform Technology

January 7, 2019

GUILFORD, Conn.--(BUSINESS WIRE)--Jan 7, 2019--Bioasis Technologies Inc.  (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced a joint research collaboration with a leading pharmaceutical company.

Under the terms of the Agreement, Bioasis will manufacture an antibody-peptide conjugate containing Bioasis’ xB 3 peptide for in vivo measurement in the CNS, enabling direct evaluation of the xB 3 platform’s delivery capabilities.

“We are excited to be working with a leading global biopharmaceutical company with an extensive track record of successfully bringing forward innovative new therapies. Entering into this research collaboration is a significant step forward in the validation of our xB 3 platform technology, and more information about this collaboration may be made available as the research progresses,” said Mark Day, Ph.D., director, president and chief executive officer. “This research collaboration provides Bioasis the opportunity to work with another premier scientific partner in addition to Prothena and further supports our efforts to positively impact disease modification of devastating neurological diseases.”

On behalf of the Board of Directors of Bioasis Technologies Inc. Mark Day, Ph.D., Director, President & Chief Executive Officer

ABOUT BIOASIS

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB 3TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, along with other statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward- looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190107005611/en/

CONTACT: Bioasis Technologies, Inc.

Catherine London

+1-917-763-2709

Catherine@bioasis.us

KEYWORD: UNITED STATES NORTH AMERICA CANADA CONNECTICUT

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE

SOURCE: Bioasis Technologies Inc.

Copyright Business Wire 2019.

PUB: 01/07/2019 08:30 AM/DISC: 01/07/2019 08:30 AM

http://www.businesswire.com/news/home/20190107005611/en

AP RADIO
Update hourly